Physician profile
Usman G Master
NPI 1922075753
$6,596.34
in general payments reported to CMS, 2019-2025
28 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $385 · 2021: $692 · 2022: $866 · 2023: $1,163 · 2024: $1,335 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.68 |
| Education | $348.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $840.80 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $742.38 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $668.58 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Opko Pharmaceuticals, LLC | $546.24 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $423.87 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $404.63 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $318.23 | 2021-2025 | |
| Travere Therapeutics, INC. | $317.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $274.45 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $266.45 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $220.46 | 2023-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $216.72 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $191.45 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $189.94 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $184.31 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147.64 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $131.85 | 2019-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.40 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $95.02 | 2023-2025 | Injectafer |
| Akebia Therapeutics INC | $94.40 | 2019-2024 | Vafseo, Auryxia |
| Amag Pharmaceuticals, INC. | $49.00 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $40.16 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.35 | 2020-2025 | |
| Outset Medical INC | $24.40 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.92 | 2023 | Oxlumo |
| Scpharmaceuticals INC. | $19.70 | 2025 | |
| Apellis Pharmaceuticals, INC. | $18.70 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Master listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.